Surufatinib Combined With Temozolomide and S-1 for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Sep 2023: Trial registered, NCT06038461
  2. 15 Sep 2023: Trial started, NCT06038461

The trials

NCT06038461: An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of Advanced Neuroendocrine Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
40 planned
Started
15 Sep 2023
Primary completion
15 Sep 2027
Arms
Surufatinib Combined With Temozolomide and S-1
Results
None posted
  1. 14 Sep 2023: Trial registered
  2. 15 Sep 2023: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.